by Katrina Carr | Dec 9, 2020 | Biomarkers
Refining management of lung cancer: ctDNA testing comes of age BY CALEB RANS, PHARMD Lung cancer is the leading cause of cancer death, accounting for 18.4% of the total cancer deaths worldwide. Despite major advances in cancer care, lung cancer is associated with a...
by Katrina Carr | Aug 6, 2020 | Biomarkers
Proteogenomic study reveals insights into early-stage lung cancer BY CALEB RANS, PHARMD FROM CELL / Novel insights into the underlying genetic and molecular architecture of lung adenocarcinoma may aid the management of patients with early-stage disease, according to...
by Katrina Carr | Dec 9, 2019 | Biomarkers
Emerging biomarkers may better guide NSCLC immunotherapy BY SUSAN LONDON credit: TheVisualMD/Science Source Emerging biomarkers hold promise for better selecting patients with non–small cell lung cancer (NSCLC) who are good candidates for immune checkpoint inhibitors,...
by Katrina Carr | Jul 16, 2019 | Biomarkers
SCLC has metabolically different, targetable subtypes BY NEIL OSTERWEIL MDedge News A diagnosis of small-cell lung cancer (SCLC) carries with it a grim prognosis. Standard therapy for extensive-stage disease, which consists of combination chemotherapy and radiation,...
by mzeal | Apr 1, 2019 | Biomarkers
Neutrophil-lymphocyte ratio predicts response to immunotherapy in NSCLC BY CHRISTINE KILGORE MDedge News SAN FRANCISCO – For patients with non–small cell lung cancer, the ratio of neutrophils to lymphocytes appears to be predictive of response to immune checkpoint...
by mzeal | Apr 1, 2019 | Biomarkers
Blood tumor mutational burden predicts immunotherapy outcomes in NSCLC BY CHRISTINE KILGORE MDedge News For patients with non–small cell lung cancer (NSCLC), a blood test of tumor mutational burden (TMB) could predict clinical responses to checkpoint inhibitors,...
